Uterine Serous Carcinoma: Increased Familial Risk for Lynch-Associated Malignancies

Serous uterine cancer is not a feature of any known hereditary cancer syndrome. This study evaluated familial risk of cancers for patients with serous uterine carcinoma, focusing on Lynch syndrome malignancies. Fifty serous or mixed serous endometrial carcinoma cases were prospectively enrolled. Pedigrees were developed for 29 probands and tumors were assessed for DNA mismatch repair (MMR) abnormalities. Standardized incidence ratios for cancers in relatives were estimated. A second-stage analysis was undertaken using data from Gynecologic Oncology Group (GOG)-210. Incidence data for cancers reported in relatives of 348 patients with serous and mixed epithelial and 624 patients with endometrioid carcinoma were compared. Nineteen of 29 (65.5%) patients in the single-institution series reported a Lynch-related cancer in relatives. Endometrial and ovarian cancers were significantly overrepresented and a high number of probands (6 of 29, 20.7%) reported pancreatic cancers. None of the probands' tumors had DNA MMR abnormalities. There was no difference in endometrial or ovarian cancer incidence in relatives of serous and endometrioid cancer probands in the case–control study. Pancreatic cancers were, however, significantly more common in relatives of patients with serous cancer [OR, 2.39; 95% confidence interval (CI), 1.06–5.38]. We identified an excess of endometrial, ovarian, and pancreatic cancers in relatives of patients with serous cancer in a single-institution study. Follow-up studies suggest that only pancreatic cancers are overrepresented in relatives. DNA MMR defects in familial clustering of pancreatic and other Lynch-associated malignancies are unlikely. The excess of pancreatic cancers in relatives may reflect an as yet unidentified hereditary syndrome that includes uterine serous cancers. Cancer Prev Res; 5(3); 435–43. ©2012 AACR.

[1]  Rochelle L. Garcia,et al.  BRCA1, TP53, and CHEK2 germline mutations in uterine serous carcinoma , 2013, Cancer.

[2]  K. Offit,et al.  Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer , 2012, Cancer.

[3]  V. Pensotti,et al.  Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy , 2012, Familial Cancer.

[4]  V. Pensotti,et al.  Contribution of germline mutations in the BRCA and PALB2 genes to pancreatic cancer in Italy , 2011, Familial Cancer.

[5]  A. Nickles Fader,et al.  Uterine Papillary Serous Carcinoma , 2011, Clinical obstetrics and gynecology.

[6]  A. Ashworth,et al.  Emerging therapeutic targets in endometrial cancer , 2011, Nature Reviews Clinical Oncology.

[7]  D. Duffy,et al.  Report of Endometrial Cancer in Australian BRCA1 and BRCA2 Mutation-Positive Families , 2011, Twin Research and Human Genetics.

[8]  L. Ellisen PARP inhibitors in cancer therapy: promise, progress, and puzzles. , 2011, Cancer cell.

[9]  Pedagógia University of Iowa Hospitals and Clinics , 2010 .

[10]  E. Friedman,et al.  The rate of the predominant Jewish mutations in the BRCA1, BRCA2, MSH2 and MSH6 genes in unselected Jewish endometrial cancer patients. , 2010, Gynecologic oncology.

[11]  E. Friedman,et al.  BRCA1/2 Germline Mutations in Jewish Patients With Uterine Serous Carcinoma , 2010, International Journal of Gynecologic Cancer.

[12]  P. Gehrig,et al.  Uterine papillary serous carcinoma: epidemiology, pathogenesis and management , 2010, Current opinion in obstetrics & gynecology.

[13]  A. Ashworth,et al.  Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. , 2009, The New England journal of medicine.

[14]  A. Secord,et al.  An updated clinicopathologic study of early-stage uterine papillary serous carcinoma (UPSC). , 2009, Gynecologic oncology.

[15]  Alison P. Klein,et al.  Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene , 2009, Science.

[16]  R. Broaddus,et al.  Endometrial cancer and Lynch syndrome: clinical and pathologic considerations. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[17]  P. Gehrig,et al.  Non-endometrioid adenocarcinoma of the uterine corpus: a review of selected histological subtypes. , 2009, Cancer control : journal of the Moffitt Cancer Center.

[18]  J. Berek,et al.  Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths. , 2008, American journal of obstetrics and gynecology.

[19]  M. Thun,et al.  Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype , 2008, Cancer Epidemiology Biomarkers & Prevention.

[20]  E. Rossi,et al.  HER‐2/neu overexpression and amplification in uterine serous papillary carcinoma , 2007, International Journal of Gynecologic Cancer.

[21]  M. Beattie,et al.  Prevalence and characteristics of pancreatic cancer in families with BRCA1 and BRCA2 mutations , 2008, Familial Cancer.

[22]  E. Weiderpass,et al.  Body size in relation to cancer of the uterine corpus in 1 million Norwegian women , 2007, International journal of cancer.

[23]  P. Møller,et al.  The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. , 2007, Gynecologic oncology.

[24]  K. Lu,et al.  Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis , 2007, Familial Cancer.

[25]  M. Kenward,et al.  An Introduction to the Bootstrap , 2007 .

[26]  J. Bernheim,et al.  High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  G. Fleming,et al.  Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma , 2006, Cancer.

[28]  A. Whittemore,et al.  Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes? , 2006, Gynecologic oncology.

[29]  W. Frankel,et al.  Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. , 2006, Cancer research.

[30]  S. Gruber,et al.  Frequency and Spectrum of Cancers in the Peutz-Jeghers Syndrome , 2006, Clinical Cancer Research.

[31]  H. Hibshoosh,et al.  HER‐2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications , 2006, International Journal of Gynecologic Cancer.

[32]  M. Hendrickson,et al.  Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers , 2006, British Journal of Cancer.

[33]  J. Boyd,et al.  Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer , 2005, Clinical Cancer Research.

[34]  P. Peltomäki,et al.  Molecular analysis of familial endometrial carcinoma: a manifestation of hereditary nonpolyposis colorectal cancer or a separate syndrome? , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. Potter,et al.  Lower cancer incidence in Amsterdam-I criteria families without mismatch repair deficiency: familial colorectal cancer type X. , 2005, JAMA.

[36]  V. Bae-Jump,et al.  Association between uterine serous carcinoma and breast cancer. , 2004, Gynecologic oncology.

[37]  K. Hemminki,et al.  Familial risk of endometrial cancer after exclusion of families that fulfilled Amsterdam, Japanese or Bethesda criteria for HNPCC. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  R. Broaddus,et al.  Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. , 2003, Gynecologic oncology.

[39]  K. Hemminki,et al.  Familial and second primary pancreatic cancers: A nationwide epidemiologic study from Sweden , 2003, International journal of cancer.

[40]  J. Ivanovich,et al.  Evaluation of the family history collection process and the accuracy of cancer reporting among a series of women with endometrial cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  A. Sood,et al.  Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma. , 2001, Gynecologic oncology.

[42]  A. Fyles,et al.  Is uterine papillary serous adenocarcinoma a manifestation of the hereditary breast-ovarian cancer syndrome? , 2000, Gynecologic oncology.

[43]  E. Levy-Lahad,et al.  BRCA1 Germline Mutations in Women With Uterine Serous Papillary Carcinoma , 2000, Obstetrics and gynecology.

[44]  H. Olsson Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[45]  Michael Thrusfield,et al.  Statistics in epidemiology: methods, techniques, and applications , 1997 .

[46]  M. Maiman,et al.  Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women. , 1997, Gynecologic oncology.

[47]  P. Cao,et al.  p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes. , 1996, Gynecologic oncology.

[48]  P. Goodfellow,et al.  Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. , 1995, The New England journal of medicine.

[49]  Hardeo Sahai,et al.  Confidence Intervals for the Mean of a Poisson Distribution: A Review , 1993 .

[50]  J. Simpson,et al.  Endometrial adenocarcinoma: genetic analysis suggesting heritable site-specific uterine cancer. , 1992, Gynecologic oncology.

[51]  Sander Greenland,et al.  Modern Epidemiology 3rd edition , 1986 .